Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from GSK

Trump’s vaccine overhaul could bring more shots, higher costs for US families

President Donald Trump's vaccine plan faces significant financial and logistical hurdles. Drugmakers must develop new manufacturing processes and conduct extensive clinical studies. Separating vaccines could lead to more appointments and increased costs for families. Public health experts question the scientific basis for the proposed changes. States retain authority to mandate…

The Economic Times

Trump's vaccine plan would require millions of individual shots last used decades ago

The biggest obstacles to President Donald Trump’s order on vaccines may be the logistical challenges it poses for U.S. parents, health providers and drugmakers

The Independent UK

GSK heads to Cambridge with long-awaited positive vibes

Pharmaceutical company’s move to new £400m research centre accompanied by encouraging news for shareholders

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Earnings tonic boosts FTSE 100 as oil falls back

Well-received earnings from Unilever, Croda and GSK spurred gains on the blue-chip FTSE 100.

Evening Standard

GSK to cut jobs amid £1.9bn cost-cutting plan and bid for faster drug development

Pharmaceuticals company is investing £400m in UK life sciences and moving scientists to new Cambridge R&D site

The Guardian - UK

GSK announces plans to close main research hub in Stevenage

IN FULL

The Independent UK

Pharma giant GSK to relocate research headquarters to Cambridge in £400m move

GSK is hoping all workers will relocate to either Cambridge or Ware

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

GSK to shut Stevenage R&D hub under plans to open new site in Cambridge

The move will impact around 1,800 staff currently based in Stevenage.

Evening Standard

FDA Just Approved a New Targeted Lung Cancer Drug: Who Qualifies for Jideytro Treatment

The FDA approved Jideytro (zidesamtinib) on July 22, 2026, for previously treated ROS1-positive non-small cell lung cancer. Here is who qualifies and what the ARROS-1 trial showed.

Medical Daily

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company…

The Economic Times

A Drug That Could Functionally Cure Hepatitis B Achieved That Goal in 1 in 5 Patients in Two Major Phase 3 Trials

Phase 3 B-Well trials published in NEJM showed bepirovirsen achieved functional cure in 20% of chronic hepatitis B patients — the first phase 3 evidence of this kind for the disease.

Medical Daily

Serum Institute partners with Gates MRI to make experimental TB vaccine

Serum Institute will manufacture an experimental tuberculosis vaccine. This novel vaccine candidate is currently in late-stage clinical trials. Gates Medical Research Institute will transfer manufacturing technology and know-how. The company plans to invest over one hundred million dollars for production. This new shot could prevent millions of cases and save…

The Economic Times

GSK's Jemperli meets main goal in mid-stage rectal cancer trial

GSK's cancer drug Jemperli met a key goal in a mid-stage trial. This drug targets a specific rectal cancer subtype affecting a small percentage of patients. Current treatments for this cancer can lead to significant lifelong side effects. Jemperli's safety profile remains consistent with prior studies in solid tumors. GSK…

The Economic Times

Haleon Just Struck a Five-Year Deal With Microsoft. Here Is What It Means for Haleon Stock.

Haleon has struck a five-year partnership with Microsoft as it looks to expand its AI transformation using Microsoft's Copilot.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Tempus AI Stock Faces a Make-or-Break Moment After Its Recent Pullback

Tempus AI's stock has hit a rough patch, but fundamentals remain solid. What does it mean for investors?

The Independent UK

What is value investing and how do I pick stocks which might rise in share price?

Patience and a good eye for judging a company’s future prospects are important - but beware the ‘value trap’

MarketBeat

MarketBeat Week in Review – 06/08 - 06/12

Stocks rallied on optimism surrounding a potential U.S.-Iran peace deal and SpaceX's historic IPO debut, reinforcing investor confidence and market momentum

MarketBeat

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK agreed to acquire Nuvalent for $10.6 billion, or $124 per share, a roughly 40% premium, to add two late-stage lung cancer assets and offset an impending patent cliff.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

FDA issues new kidney warning for weight loss pill

Alli was the first over-the-counter weight loss pill approved by the U.S. Food and Drug Administration

Barchart

Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

AAP

More swings for AI stocks drag Wall Street back on the roller coaster

More sudden reversals for high-flying artificial-intelligence stocks sent Wall Street reeling

AAP

Another sell-off for AI stocks sends Wall Street reeling

Another sell-off for artificial-intelligence stocks whipsawed Wall Street

The Economic Times

Why is the US stock market crashing today? S&P 500 erases all gains and wipes out $1.3 trillion in 2 hours as Nasdaq and Dow turn sharply lower - Tech stocks and chip sector collapse

The US stock market crash today caught many investors off guard. Early gains quickly vanished as the S&P 500 erased more than $1.3 trillion in market value within just two hours. What began as a relief rally suddenly turned into a broad sell-off that dragged down the Nasdaq, Nvidia, Apple,…

AAP

Another sell-off for AI stocks drags Wall Street sharply lower

Another sell-off for artificial-intelligence stocks is dragging Wall Street sharply lower

AAP

Wall Street falls sharply as AI stocks resume their sell-off

Artificial-intelligence stocks are resuming their sell-off, and the former superstars that had led the market to records are dragging Wall Street down with them

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.